Comprehensive Study Guide: Immunology and Vaccine Development

Importance and Impact of Vaccines

• Vaccines have led to a striking decrease in the incidence of infectious diseases in the United States. Following are historical peaks compared to 2014 data:   - Diphtheria: Maximum cases in 1921 totaled $206,939$. In 2014, there were $0$ cases, representing a $-99.99\%$ change.   - Measles: Maximum cases in 1941 totaled $894,134$. In 2014, there were $669$ cases, representing a $-99.93\%$ change.   - Mumps: Maximum cases in 1968 totaled $152,209$. In 2014, there were $737$ cases, representing a $-99.51\%$ change.   - Pertussis: Maximum cases in 1934 totaled $265,269$. In 2014, there were $10,631$ cases, representing a $-95.99\%$ change.   - Polio (paralytic): Maximum cases in 1952 totaled $21,269$. In 2014, there were $0$ cases, representing a $-100.0\%$ change.   - Rubella: Maximum cases in 1969 totaled $57,686$. In 2014, there were $2$ cases, representing a $-99.99\%$ change.   - Tetanus: Maximum cases in 1923 totaled $1,560$. In 2014, there were $8$ cases, representing a $-99.48\%$ change.   - Haemophilus influenzae type B: Maximum cases in 1984 totaled $\sim 20,000$. In 2014, there were $34$ cases, representing a $-99.83\%$ change.   - Hepatitis B: Maximum cases in 1985 totaled $26,611$. In 2014, there were $1,098$ cases, representing a $-95.87\%$ change.

Definition and Functional Benefits

• Formal Definition: A vaccine is a substance used to stimulate the production of antibodies and provide immunity against one or several diseases.   - It is prepared from the causative agent of a disease, its products, or a synthetic substitute.   - It is treated to act as an antigen without inducing the actual disease.
• Physiological Process: It represents an active process of acquiring adaptive immunity.
• Primary Benefits:   - Individuals are significantly less likely to contract the targeted disease.   - If infection does occur, symptoms are typically reduced.   - Helps prevent serious bodily damage from the pathogen.

Historical Origins of Vaccines

• Smallpox (Variola virus): Characterized by fever, rash, and scabbing. Scabs fall off to leave deeply pocked skin. Primarily fatal in children.   - Variolation: An early practice observed in China and other societies involving the administration of pus from scabs into healthy individuals. This resulted in mild symptoms but generally conferred protection.
• Edward Jenner (1749\text{--}1823):   - English physician who observed that milkmaids who contracted cowpox did not get smallpox.   - Conducted an experiment injecting matter from a cowpox pustule into the arm of a boy, resulting in a small scab and soreness.   - Re-injecting the boy 6 weeks later resulted in no illness.   - Etymology: The word "vaccination" is derived from the Latin "vacca" meaning cow.
• Louis Pasteur (1822\text{--}1895):   - French scientist who developed bacterial culturing techniques.   - Established the "Germ theory of disease."   - Developed vaccines for anthrax and rabies.   - Notable for fermentation and pasteurization (heating liquids to high temperatures to kill bacteria).

Characteristics and Challenges of Vaccine Development

• Characteristics of an Ideal Vaccine:   - Safety: Must not cause the disease it aims to prevent.   - Stability: Must remain effective during storage and transport (e.g., cold chain requirements).   - Affordability: Must be accessible for widespread use.   - Appropriate Immune Response: Must induce the correct combination of B cell, CD4+, and CD8+ responses.     - Inducing CD8+ (Cytotoxic T cell) responses is considered the most challenging.   - Life-long Immunity: Ideally requires as few boosters as possible.
• Challenges of Re-infection: Reasons why pathogens may be encountered more than once despite prior exposure:   - Initial infection fails to stimulate a sufficient antibody response.   - Pathogen mutations (antigenic drift/shift) mean memory cells no longer recognize the agent.   - Immune memory can wane over time.   - Low frequency of pathogen encounter may reduce the "refreshing" of immune memory.

Classification and Types of Vaccines

• Inactivated: The pathogen is rendered non-infectious, usually via heat or chemicals.
• Live-attenuated: Uses a significantly weakened version of the pathogen.
• Toxoid: Uses an inactivated version of the toxin produced by the disease-causing agent.
• Viral Vector: Uses a different, harmless viral shell to deliver genetic material (nucleic acids) to host cells.
• Subunit: Uses specific fragments or pieces of the pathogen.
• mRNA: Utilizes host cells to synthesize the microbial antigen themselves.

The Immunological Mechanism of Vaccine Response

1. Antigen Introduction: Via syringe (injection) or de novo host synthesis (as seen in viral vector and mRNA vaccines).
2. Transport: Collection and transportation of the antigen to Secondary Lymphoid Organs (SLO).
3. Antigen Presentation:     - B cells interact with antigens via follicular Dendritic Cells (DCs).     - T cells interact with antigens via standard Dendritic Cells.
4. Effector and Memory Triggering:     - Antibody Optimization: Includes processes like affinity maturation and isotype switching.     - Cellular Responses: Secretion of cytokines by Th (Helper T) cells and the activation of CTLs (Cytotoxic T Lymphocytes) in some cases.

Common Points of Failure/Problems in Vaccine Efficacy

• Antigen Release: Issues with the rate of release or premature degradation.
• Antigen Delivery: Failure of sufficient cells to transport the antigen to the SLO.
• Activation Barriers:   - Immune response capabilities decrease with age (immune senescence).   - Production of non-neutralizing antibodies, which fail to prevent infection.   - Antibody-Dependent Enhancement (ADE): The enhancement of infection via Fc receptors.
• T cell response: Ensuring the proper T cell profile is activated.

Adjuvants: History and Function

• Discovery: Gaston Ramon (1886\text{--}1963), a French veterinarian working on diphtheria vaccines for horses, discovered that horses that developed abscesses at the injection site produced higher levels of anti-DT (Diphtheria Toxoid) antibodies.
• Etymology: Derived from the Latin "adjuvar," meaning to help or aid.
• Mechanisms of Action:   - Historical View: Believed to create a reservoir for the slow release of antigen (the "depot effect").   - Modern Understanding: Adjuvants activate the innate immune system by creating localized inflammation.   - Process: Recruits leukocytes (monocytes, neutrophils, lymphocytes), triggers cytokine release, and promotes the differentiation of monocytes into macrophages (MGs) and Dendritic Cells (DCs).   - Result: Enhanced antigen uptake, processing, and transport to SLOs, leading to increased antigen presentation to naïve B and T cells.
• Benefits of Adjuvants:   - Dose Sparing: Using less antigen to increase global supply.   - Rapid Response: Useful for post-exposure prophylaxis.   - Response Broadening: Improving efficacy for complex diseases like HIV, Malaria, or Influenza.   - Elderly Populations: Overcoming immune senescence.
• Common Adjuvant Examples:   - Aluminum Salts (Alum): One of the most long-standing adjuvants.   - AS04: Combination of a lipid and an aluminum salt.   - MF59: An oil-in-water emulsion containing squalene.   - CpG: An oligonucleotide.

COVID-19 Vaccines

• Technological Platforms:   - mRNA: (Pfizer/BioNTech, Moderna) Uses lipid nanoparticles for delivery.   - DNA/Viral Vector: (Johnson and Johnson/Janssen, Oxford/AstraZeneca) Uses an adenovirus vector.
• Mechanism:   - Spike protein nucleic acid is injected intramuscularly (IM).   - mRNA is translated directly into protein; DNA is transcribed to mRNA and then translated to protein.   - The resulting Spike protein antigen is taken up by macrophages/DCs, transported to lymph nodes (LN), and presented to naïve B and T cells.
• Efficacy Success Factors: These vaccines have shown extreme effectiveness. Potential reasons for high success compared to other pathogens include the specific immunogenicity of the spike protein, the amount/availability of the antigen, and the inherent properties of mRNA potentially acting as its own adjuvant.